Sort
10,766 grants matching “checkpoint inhibitor”
Tailoring CAR T cell therapy for Hodgkin Lymphoma
$634,693Barbara Savoldo · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells
$634,675Mehmet Toner · Massachusetts General Hospital · R01 · FY2023 · CA
Data Processing, Analysis and Modeling Unit
$634,673Jeremy Goecks · Oregon Health & Science University · U2C · FY2018 · CA
Antigen-specific âkick and killâ of the latent HIV reservoir using dendritic cells
$634,631Robbie B Mailliard · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · AI
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer
$634,454Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2021 · CA
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC
$634,298Satdarshan Singh Monga · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · CA
Tumor-associated pDC (TApDC) in liver cancer with HIV infection
$634,061Lishan Su · University Of Maryland Baltimore · R01 · FY2025 · CA
Genotypes and Phenotypes of Apoptosis and Risk of Head and Neck Cancer
$634,010Qingyi Wei · University Of Tx Md Anderson Can Ctr · R01 · FY2010 · CA
Improving IL12 Immunogene Therapy for Glioblastoma Based on Human Clinical Trial Results
$633,656E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2024 · NS
Improving IL12 Immunogene Therapy for Glioblastoma Based on Human Clinical Trial Results
$633,656E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2025 · NS
Uncovering the metabolic underpinnings of T cell exhaustion
$633,550Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AI
Population Modeling of Bladder Cancer Detection and Control
$633,411Thomas Trikalinos · Brown University · U01 · FY2024 · CA
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
$633,409Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2025 · CA
Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines
$633,201James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Targeting STAT3 to enhance anti-tumor immunity
$633,201Daniel E Johnson · University Of California, San Francisco · R01 · FY2019 · DE
Molecular Targeting of Diffuse Large B-cell Lymphoma
$633,103Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R01 · FY2010 · CA
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
$632,873Elias Sayour · University Of Florida · R37 · FY2025 · CA
Immunological consequences of LINE-1 expression in cancer
$632,855Katherine B Chiappinelli · George Washington University · R01 · FY2025 · CA
Optimizing immunoradiotherapy for HNSCC
$632,764Joseph A Califano · University Of California, San Diego · R01 · FY2024 · CA
Project 3: Tools for Capturing Immune Cell/Cancer Cell Interactions in Cancer Immunotherapies and Combination Immunotherapies
$632,739James R. Heath · Institute For Systems Biology · U54 · FY2019 · CA
Radiation and dendritic cells to hepatomas to improve immunotherapy response
$632,389Sean S Park · Mayo Clinic Rochester · R01 · FY2022 · CA
Targeting B7-H3 in ovarian cancer
$632,310Gianpietro Dotti · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung Cancer
$632,185Zihai Li · Ohio State University · R01 · FY2025 · CA
Innate NLRC4 signaling controls adaptive immune responses
$632,133Fayyaz S. Sutterwala · Cedars-Sinai Medical Center · R01 · FY2025 · AI
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism
$632,109Nicholas C Denko · Ohio State University · R01 · FY2022 · CA